The prophylactic effect of tropisetron on epidural morphine-related nausea and vomiting: a comparison of dexamethasone with saline

Tropisetron is a 5-hydroxytryptamine subtype 3 receptor antagonist that is primarily used in the prevention of chemotherapy-induced nausea and vomiting. We evaluated the prophylactic effect of tropisetron on postoperative nausea and vomiting associated with epidural morphine. Dexamethasone and saline served as controls. One-hundred twenty women (n = 40 in each of three groups) undergoing abdominal total hysterectomy under epidural anesthesia were enrolled in this randomized, double-blinded, and placebo-controlled study. At the end of surgery, Group 1 received IV tropisetron 5 mg, whereas Groups 2 and 3 received dexamethasone 5 mg and saline, respectively. We found that tropisetron did not significantly reduce the occurrence of nausea and vomiting associated with epidural morphine. Dexamethasone, however, reduced the total incidence of nausea and vomiting from 59% to 21% (P < 0.01) and the percentage of patients requiring rescue antiemetic from 38% to 13% (P < 0.05). We conclude that IV tropisetron 5 mg did not prevent the occurrence of postoperative nausea and vomiting associated with epidural morphine. IV dexamethasone 5 mg was effective for this purpose. IMPLICATIONS: We compared the prophylactic IV administration of tropisetron 5 mg to prevent postoperative nausea and vomiting (PONV) associated with epidural morphine with dexamethasone 5 mg and saline in women undergoing hysterectomy. We found that tropisetron 5 mg did not significantly reduce the occurrence of PONV associated with epidural morphine. Dexamethasone 5 mg was effective for this purpose.     

几种药物预防腹腔镜胆囊切除术后恶心呕吐的对比研究

目的比较格拉司琼、氟哌利多、地塞米松单用或合用预防腹腔镜胆囊切除术后恶心呕吐的效果。方法择期腹腔镜胆囊切除术患者160例,于麻醉前随机分为四组,静脉注入各预防性药物,A组：地塞米松10mg;B组：氟哌利多2．5mg;C组：氟哌利多2．5mg＋地塞米松10mg;D组：格拉司琼3mg。观察术后24h恶心呕吐发生率。结果四组术后24h恶心呕吐总发生率分别为78％、63％、25％、28％,C组和D组明显低于A组和B组（P〈0．01）,而C组与D组差异无统计学意义。结论格拉司琼、氟哌利多、地塞米松都有预防腹腔镜胆囊切除术后恶心呕吐的作用,但以格拉司琼和氟哌利多＋地塞米松效果显著,而且氟哌利多＋地塞米松更显示其性价比优越性。     

Prevention of post-operative nausea and vomiting with combined granisetron and droperidol in women undergoing thyroidectomy

We have compared the efficacy and safety of combined granisetron and droperidol with each anti-emetic alone for preventing post-operative nausea and vomiting after thyroidectomy. In a prospective, randomized, double-blind study, 180 women received granisetron 40 micrograms kg-1, droperidol 20 micrograms kg-1, or granisetron 40 micrograms kg-1 plus droperidol 20 micrograms kg-1 (n = 60 of each) intravenously immediately before induction of anaesthesia. A standard general anaesthetic technique and post-operative analgesia were used. A complete response, defined as no post-operative nausea and vomiting and no need for another rescue anti-emetic, during the first 24 h after anaesthesia occurred in 88%, 60% and 98% of patients who had received granisetron, droperidol and granisetron plus droperidol (P < 0.05; overall Fisher's exact probability test). No clinically important adverse events due to the drugs were observed in any of the groups. In summary, prophylactic use of combined granisetron and droperidol is more effective than each drug alone for the prevention of post-operative nausea and vomiting in female patients undergoing thyroidectomy.     

The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study

We sought to determine the minimum effective dose of dexamethasone in preventing postoperative nausea and vomiting in women undergoing thyroidectomy. Two hundred twenty-five women (n = 45 in each of five groups) undergoing thyroidectomy under general anesthesia were enrolled in this randomized, double-blinded, placebo-controlled study. Immediately after the induction of anesthesia, patients received IV dexamethasone at doses of 10 mg (D10), 5 mg (D5), 2.5 mg (D2.5), 1.25 mg (D1.25), or saline (S). We found that Groups D10 and D5 were significantly different from Group S in the total incidences of nausea and vomiting, more than four vomiting episodes, the proportions of patients requiring rescue antiemetics, and the incidences of complete responses. The differences between Groups D10 and D5 were not significant. Dexamethasone 2.5 mg reduced the total incidence of nausea and vomiting. Dexamethasone 1.25 mg was not effective. Dexamethasone 5 mg IV is the minimum effective dose in preventing postoperative nausea and vomiting in women undergoing thyroidectomy.     

A dose ranging study of dexamethasone for preventing patient-controlled analgesia-related nausea and vomiting: a comparison of droperidol with saline

We designed this study to determine the minimum dose of dexamethasone for preventing nausea and vomiting associated with the use of morphine by patient-controlled analgesia (PCA). Two hundred forty female patients were randomly assigned to receive dexamethasone 2, 4, 8, or 12 mg IV immediately before induction of anesthesia. Droperidol (0.1 mg/mL with morphine 1 mg/mL in PCA pump) and saline were used as controls. The complete response (no postoperative nausea and vomiting and no need for rescue antiemetic for a 24-h postoperative period) rates for dexamethasone 8 mg (72.2%) and 12 mg (78.9%) were significantly more than for saline (42.9%) (P < 0.05). Patients who received dexamethasone 12 or 8 mg also reported higher patient satisfaction than those who received saline (P < 0.05). These results were as effective as adding droperidol 0.1 mg/mL to the morphine PCA without causing drowsiness, restlessness, or arrhythmias. Smaller doses of dexamethasone (4 or 2 mg) were not effective for this propose. The results suggest that dexamethasone 8 mg IV is the minimum effective dose for the reduction of PCA morphine-related nausea and vomiting. IMPLICATIONS: Morphine administration by patient-controlled analgesia (PCA) is often associated nausea and vomiting. In this double-blind study, the minimum effective dose of dexamethasone for reducing this complication was 8 mg. This was as effective as adding droperidol 0.1 mg/mL to the morphine PCA without causing drowsiness, restlessness or arrhythmias.     

Double-blind comparison of ondansetron, droperidol and saline in the prevention of postoperative nausea and vomiting

We have compared the efficacy of ondansetron with droperidoland saline in the prevention of postoperative nausea and vomiting(PONV) in 120 ASA I and If patients undergoing hip and kneereplacements and femoral resections. They received a standardizedcombined extradural and general anaesthetic and at the end ofsurgery were allocated randomly to receive droperidol 1.25 mg,ondansetron 4mg or 0.9% saline in a 25-ml bag. An extraduralmixture containing 0.5% plain bupi-vacaine 10 ml, fentanyl 500µg and saline 30 ml was infused and PONV assessed for24 h. Both ondansetron and droperidol were superior to salinein preventing vomiting (P < 0.01) although there was no significantdifference between them. The incidence of vomiting was 17% forondansetron, 18% for droperidol and 45% for saline. There wasno significant difference in the incidence of nausea betweenthe groups. Metoclopramide, the rescue antiemetric, was demandedby 38%, 34% and 17% of patients receiving saline, droperidoland ondansetron, respectively (ondansetron vs dro -peridol P<0.05).(Br. J. Anaesth. 1994; 72: 544–547)     

Prevention of postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery--granisetron alone vs granisetron combined with dexamethasone/droperidol

BACKGROUND AND OBJECTIVES: Laparoscopic bariatric surgeries are associated with an appreciably high rate of postoperative nausea and vomiting. This study was designed to compare the effectiveness of granisetron either alone or in combination with droperidol or dexamethasone, for the prevention of post operative nausea and vomiting (PONV) in patients undergoing laparoscopic bariatric surgeries. METHODS: In a randomized, double-blind, placebo-controlled trial, 120 patients received either Granisetron 1 mg, Granisetron 1 mg plus Droperidol 1.25 mg, Granisetron 1 mg plus Dexamethasone 8 mg or Placebo (saline), intravenously immediately before induction of anesthesia. Perioperative anesthetic care was standardized in all patients. Patients were then observed for 24 hours after administration of the study drugs. RESULTS: The incidence of PONV was 30% with granisetron alone, 30% with granisetron plus droperidol, 20%, with granisetron plus dexamethanone, and 67% with placebo. (P < 0.05; overall Fisher's exact probability test). The incidence of adverse events was not different among the 4 groups. CONCLUSION: Graniserton is effective and safe drug for reducing the incidence of PONV in patients undergoing bariatric surgeries, and becomes highly effective when combined with dexamethasone.     

The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting

We evaluated the timing effect of a 10-mg IV administration of dexamethasone on its efficacy as a prophylactic antiemetic on postoperative nausea and vomiting (PONV). One hundred twenty women (n = 40 in each of three groups) undergoing abdominal total hysterectomy under general anesthesia were enrolled in this randomized, double-blinded, placebo-controlled study. Group 1 received dexamethasone before the induction of anesthesia, Group 2 received dexamethasone at the end of anesthesia, and Group 3 received placebo (saline). The incidence of PONV was evaluated. During the postoperative period of 0-2 h, patients in Group 1 reported a less frequent incidence of PONV (15%) than those in Groups 2 and 3 (45% and 53%, respectively). Patients in Group 1 also requested less rescue antiemetic (8%) than those in Groups 2 and 3 (30% and 35%, respectively). During the postoperative period of 2-24 h, patients in both Groups 1 and 2 reported less frequent incidences of PONV (25% and 28%) and requested fewer rescue antiemetics (13% and 15%) than those in Group 3 (55% and 38%, respectively). In conclusion, the prophylactic IV administration of dexamethasone immediately before the induction, rather than at the end of anesthesia, was more effective in preventing PONV. IMPLICATIONS: We evaluated the effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic on postoperative nausea and vomiting. We found that dexamethasone, when given immediately before the induction of anesthesia, was more effective than when given at the end of anesthesia.     

Small-dose dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy: a comparison of tropisetron with saline

Dexamethasone is an effective antiemetic drug, but the efficacy of small-dose dexamethasone 5 mg on the prophylaxis of postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy has not been evaluated. We, therefore, evaluated the prophylactic effect of small-dose dexamethasone (5 mg) on PONV in patients undergoing laparoscopic cholecystectomy. Tropisetron and saline served as controls. One-hundred-twenty patients scheduled for laparoscopic cholecystectomy were enrolled in a randomized, double-blinded, placebo-controlled study. At the induction of anesthesia, the Dexamethasone group received IV dexamethasone 5 mg, the Tropisetron group received IV tropisetron 2 mg, and the Placebo group received IV saline. We found that both dexamethasone and tropisetron significantly decreased the following variables: the total incidence of PONV (P < 0.01), more than four vomiting episodes (P < 0.05), and the proportions of patients requiring rescue antiemetics (P < 0.05). The differences between the Dexamethasone and Tropisetron groups were not significant. We conclude that prophylactic IV dexamethasone 5 mg significantly reduces the incidence of PONV in patients undergoing laparoscopic cholecystectomy. At this dose, dexamethasone is as effective as tropisetron 2 mg and is more effective than placebo. IMPLICATIONS: We evaluated the prophylactic effect of small-dose dexamethasone (5 mg) on postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy. Tropisetron (2 mg) and saline served as controls. We found that dexamethasone 5 mg (IV) significantly reduced the incidence of PONV in these patients, and, at this dose, dexamethasone was as effective as tropisetron and was more effective than placebo.     

Low-dose dexamethasone reduces nausea and vomiting after epidural morphine: a comparison of metoclopramide with saline

STUDY OBJECTIVE: To compare the efficacy of a low dose of dexamethasone (5 mg) with metoclopramide 10 mg and saline in preventing nausea and vomiting after epidural morphine in posthysterectomy analgesia. DESIGN: Randomized, placebo-controlled study. SETTING: Inpatient surgery at Municipal Women's and Children's General Hospital. PATIENTS: 120 ASA physical status I and II women receiving epidural morphine for posthysterectomy analgesia. INTERVENTIONS: All patients received epidural morphine 3 mg for postoperative analgesia. The dexamethasone group (n = 40) received dexamethasone 5 mg, the metoclopramide group (n = 40) received metoclopramide 10 mg, and the saline group (n = 40) received saline. MEASUREMENTS AND MAIN RESULTS: The occurrence of nausea and vomiting appeared more frequently during 6 to 24 hours following the administration of epidural morphine. The total frequency of nausea and vomiting in the dexamethasone group was significantly lower than that of the metoclopramide and saline groups during this period, with reporting frequencies of 21%, 49%, and 53%, respectively (p <.05 each). However, the difference between metoclopramide and saline did not reach statistical significance. CONCLUSIONS: Dexamethasone 5 mg was more effective than metoclopramide or saline in the prevention of nausea and vomiting associated with epidural morphine for postoperative analgesia.     

Comparison of the incidence of postoperative nausea and vomiting between women undergoing open or robot-assisted thyroidectomy

Background

Open thyroidectomy is associated with a high incidence of postoperative nausea and vomiting (PONV) in up to 70 % of cases. Use of the recently introduced robot-assisted endoscopic thyroidectomy using a gasless transaxillary approach has been increasing because of its several advantages over open thyroidectomy. This study compared the incidence of PONV in the women who underwent open or robot-assisted thyroidectomy.

Methods

This prospective, double-blinded study enrolled 170 women 20–60 years of age who were scheduled for conventional open thyroidectomy (group O) or robot-assisted thyroidectomy (group R). A standard anesthetic technique, including sevoflurane and air in oxygen, was used. During a 0–24-h postoperative period, the presence and severity of PONV (nausea, retching/vomiting), severity of pain, need for rescue antiemetics, and the degree of patient satisfaction were evaluated.

Results

During the 0–6-h postoperative period, the incidence of PONV and mean pain score (40.0 vs. 51.8 %and 4.2 vs. 4.8 in groups R and O, respectively) were not significantly different. At 6–24 h postoperatively, the incidence of PONV (18.8 vs. 44.7 %), severe emesis (11.8 vs. 29.4 %) and mean pain score (2.8 vs. 3.8) were significantly lower in group R compared to group O, respectively. Overall, the incidence of PONV (42.4 vs. 63.5 %) and severe emesis (20.0 vs. 43.5 %) were significantly lower in group R compared to group O, respectively. The incidence of satisfied patients 6 and 24 h after the end of anesthesia (55.3 vs. 28.2 and 82.4 vs. 58.8 %) were significantly higher in group R compared to group O, respectively.

Conclusions

Robotic thyroidectomy reduces the incidence and severity of PONV compared to open thyroidectomy during a 0–24-h postoperative period.     

Efficacy of dexamethasone for reducing postoperative nausea and vomiting and analgesic requirements after thyroidectomy.

OBJECTIVE: To evaluate the efficacy of dexamethasone for reducing postoperative nausea and vomiting (PONV) and analgesic requirements after thyroidectomy. STUDY DESIGN AND SETTING: In a prospective, randomized, double-blind, placebo-controlled study, 75 patients, 20 men and 55 women, received intravenously placebo or dexamethasone at 2 different doses (4 and 8 mg) (n=25 of each) at the end of surgery. A standard general anesthetic technique was used. PONV and analgesic requirements were evaluated. RESULTS: The rate of patients experiencing PONV during the first 24 hours after anesthesia was 64% with dexamethasone 4 mg (P=0.269) and 28% with dexamethasone 8 mg (P=0.001), compared with placebo (76%). The need of indomethacin for intolerable pain was less in patients who had received dexamethasone 8 mg than in those who had received placebo (P=0.009). CONCLUSION: Dexamethasone 8 mg effectively decreases PONV and analgesic requirements after thyroidectomy.     

5-羟色胺受体拮抗剂与氟哌利多预防术后恶心呕吐效果的Meta分析

目的 采用Meta分析比较5-羟色胺(5-hydroxytryptamine,5-HT3)受体拮抗剂与氟哌利多预防术后恶心呕吐(postoperative nausea and vomiting,PONV)的效果. 方法 检索Cochrane图书馆、Pubmed、EMBASE、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、重庆维普中文科技期刊全文数据库(VIP)、万方数据库,检索时间从建库至2013年9月.收集所有比较5-HT3受体拮抗剂与氟哌利多用于预防全麻PONV的文献.采用Cochrane协作网系统评价法评价纳入文献的质量,采用RevMan 5.1软件对收集的患者资料进行Meta分析评价. 结果 共纳入17项随机对照试验(randomized controlled trial,RCT),1 823例患者.Meta分析结果显示:与氟哌利多比较,5-HT3受体拮抗剂能降低全麻患者PONV(术后0～24 h)[比值比(RR)=0.49,95％可信区间(CI)=0.39～0.63]与呕吐(RR=0.54,95％CI=0.43～0.67)的发生率.亚组分析结果表明,昂丹司琼预防PONV(RR=0.67,95％CI=0.47～0.96)与呕吐(RR=0.56,95％CI=0.39～0.82)的发生较氟哌利多更好;格拉司琼预防PONV (RR=0.42,95％CI=0.30～0.58)与呕吐(RR=0.58,95％CI=0.42～0.81)的发生较氟哌利多更好.5-HT3受体拮抗剂与氟哌利多预防术后恶心的效果相当(RR=0.89,95％CI=0.77～1.04).昂丹司琼(RR=0.88,95％CI=0.67～1.14)或格拉司琼(RR=0.94,95％CI=0.75～1.17)与氟哌利多预防术后恶心的效果相当.与氟哌利多比较较,5-HT3受体拮抗剂组头痛发生率明显增加(RR=1.44,95％CI=1.12～1.84);5-HT3受体拮抗剂与氟哌利多术后头晕(RR=I.19,95％CI=0.88～1.62)、嗜睡(RR=1.24,95％CI=0.34～4.49)的发生率相同. 结论 与氟哌利多比较,5-HT3拮抗剂预防全麻患者PONV效果较好.     

Reduction of postoperative nausea and vomiting and analgesic requirement with dexamethasone in women undergoing general anesthesia for mastectomy

Dexamethasone has antiemetic and analgesic effects in various types of surgery. In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of dexamethasone for reducing postoperative nausea and vomiting (PONV) and analgesic requirement in women undergoing general anesthesia for mastectomy. Patient were allocated randomly to one of three groups (n=30 of each) to receive intravenously either placebo or dexamethasone at two different doses (4 mg, 8 mg) at the end of surgery. Postoperatively, emetic episodes and analgesic requirement were evaluated by an investigator. Patient demographics and types of surgery were not different among the treatment groups. The rate of patients experiencing PONV during 0-24 hours after anesthesia was 33% with dexamethasone 4 mg (p=0.01) and 27% with dexamethasone 8 mg (p=0.002), compared with placebo (67%). The need of indomethacin for intolerable pain was less in patients who had received dexamethasone 8 mg than in those who had received placebo (p=0.001) or dexamethasone 4 mg (p=0.034). No difference in analgesic requirement was found between the dexamethasone 4 mg and placebo groups (p=0.18). No clinically serious adverse events attributed to the study drug were observed in any of the groups. We conclude that dexamethasone 8 mg effectively decreases PONV and analgesic requirement in women undergoing general anesthesia for mastectomy.     

RETRACTED ARTICLE: Prevention of postoperative nausea and vomiting with granisetron: a randomized,double-blind comparison with droperidol

The effects of granisetron for preventing postoperative nausea and vomiting were investigated in a randomized, double-blind comparison with droperidol and placebo in 100 patients undergoing general anaesthesia for major gynaecological surgery. The patients received a single dose of either granisetron (40 μg · kg^{? 1}, n = 25), dropéridol (1.25 mg, n = 25; 2.5 mg n = 25) or placebo (saline, n = 25) iv over two to five minutes immediately before induction of anaesthesia. The antiemetic effects of these drugs were evaluated during the first three and the next 21 hr after recovery from anaesthesia. During 0– 3 hr after anaesthesia, the frequency of nausea and vomiting was 60%, 12%, 16% and 12% after administration of placebo, granisetron, droperidol 1.25 mg or droperidol 2.5 mg, respectively. The corresponding frequencies during 3– 24 hr after anaesthesia were 44%, 8%, 36% and 12%. The efficacy of granisetron in preventing postoperative nausea and vomiting was almost equal to that of droperidol 2.5 mg. The awakening time in the patients who had received droperidol 2.5 mg was prolonged by approximately three minutes compared with the placebo group (P < 0.05), and postoperative drowsiness/sedation was observed in these patients. In conclusion, preoperative prophylactic administration of granisetron is superior to that of droperidol in the prevention of postoperative nausea and vomiting after anaesthesia.     

A comparison of the effects of droperidol and the combination of droperidol and ondansetron on postoperative nausea and vomiting for patients undergoing laparoscopic cholecystectomy

STUDY OBJECTIVES: To compare the prophylactic antiemetic efficacy of the combination of ondansetron and droperidol with that of droperidol alone in patients undergoing elective laparoscopic cholecystectomy. DESIGN: Randomized, double-blind controlled trial.University affiliated teaching hospital after induction of standardized general anesthesia. PATIENTS: 64 ASA physical status I or II patients aged 18 to 80 years, undergoing elective laparoscopic cholecystectomy. INTERVENTION: Following induction of general anesthesia, patients received either droperidol 1.25 mg intravenously (IV; n = 30; Group D) or the combination of droperidol 1.25 mg IV and ondansetron 4 mg IV (n = 34; Group D+O). MEASUREMENTS: Number and severity of nausea episodes, number of emetic episodes, total analgesic consumption, and rescue antiemetic administration were assessed at 1, 3, and 24 hours after admission to the recovery room. Data were analyzed using Fisher's Exact test and unpaired Student's t-test; a p-value <0.05 was considered significant. RESULTS: The proportions of patients who experienced nausea (70% and 53% for D and D+O groups, respectively) and vomiting (30% and 19% for D and D+O groups, respectively) were similar in the two groups. The frequency of moderate and severe nausea (requiring administration of antiemetic) was less in group D + O (7%) compared with group D (19%; p < 0.05). CONCLUSIONS: Patients who received the combination of droperidol and ondansetron experienced less severe nausea compared with patients who received droperidol alone.